D&O Ongoing Disclosure Notices

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
7 March 2022
Date of last disclosure:
20 September 2021
Director or senior manager giving disclosure
Full name(s):
Andrew Robert Donald Somervell
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Not Applicable
Position held in listed issuer:
Vice President - Products & Technology
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial interest in shares issued to a trustee under an
Employee Share Scheme
For that relevant interest
Number held in class before acquisition or disposal:
67,800
Number held in class after acquisition or disposal:
67,888
Current registered holder(s):
Andrew Robert Donald Somervell
Registered holder(s) once transfers are registered:
Andrew Robert Donald Somervell
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under
the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
One

Details of transactions requiring disclosure-
Date of transaction:
28-Jan-20
Nature of transaction: Participation in Employee Share Purchase Scheme
Name of any other party or parties to the transaction (if known):
Fisher & Paykel Healthcare Employee Share Purchase
Trustee Limited
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily converted into a
cash value, describe the consideration:$1,490.81
Number of financial products to which the transaction related:
88
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were aquired or disposed of during a closed period:
Not applicable
Whether prior written clearance was provided to allow the aquisition or disposal to proceed
during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
(a) Options to acquire Ordinary Shares
(b) Peformance Share Rights
Nature of relevant interest:
(a) Beneficial
(b) Beneficial
For that relevant interest,-
Number held in class:
(a) 144,323
(b) 42,631
Current registered holder(s):
Andrew Robert Donald Somervell
For a derivative relevant interest,-
Type of derivative:
Not applicable
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under
the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Cerification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons for
whom it is made.
Signature of director or officer:
Date of signature:7 March 2022
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
7 March 2022
Date of last disclosure:
7 March 2022
Director or senior manager giving disclosure
Full name(s):
Andrew Robert Donald Somervell
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Not Applicable
Position held in listed issuer:
Vice President - Products & Technology
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial interest in shares issued to a trustee under an
Employee Share Scheme
For that relevant interest
Number held in class before acquisition or disposal:
90,887
Number held in class after acquisition or disposal:
90,922
Current registered holder(s):
Andrew Robert Donald Somervell
Registered holder(s) once transfers are registered:
Andrew Robert Donald Somervell
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under
the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
One

Details of transactions requiring disclosure-
Date of transaction:
28-Feb-22
Nature of transaction: Participation in Employee Share Purchase Scheme
Name of any other party or parties to the transaction (if known):
Fisher & Paykel Healthcare Employee Share Purchase
Trustee Limited
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily converted into a
cash value, describe the consideration:$491.96
Number of financial products to which the transaction related:
35
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were aquired or disposed of during a closed period:
Not applicable
Whether prior written clearance was provided to allow the aquisition or disposal to proceed
during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
(a) Options to acquire Ordinary Shares
(b) Peformance Share Rights
Nature of relevant interest:
(a) Beneficial
(b) Beneficial
For that relevant interest,-
Number held in class:
(a) 109,826
(b) 25,656
Current registered holder(s):
Andrew Robert Donald Somervell
For a derivative relevant interest,-
Type of derivative:
Not applicable
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under
the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Cerification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons for
whom it is made.
Signature of director or officer:
Date of signature:7 March 2022
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
7 March 2022
Date of last disclosure:
20 September 2021
Director or senior manager giving disclosure
Full name(s):
Lewis George Gradon
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Executive Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial interest in shares issued to a trustee
under an Employee Share Scheme
For that relevant interest:
Number held in class before acquisition or disposal:
562,280
Number held in class after acquisition or disposal:
562,351
Current registered holder(s):
Lewis George Gradon; Gradon Family Trust
Registered holder(s) once transfers are registered:
Lewis George Gradon; Gradon Family Trust
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Not Applicable
Class of underlying financial products:
Details of affected derivative:
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative:
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: One
Details of transactions requiring disclosure:
Date of transaction:
28 February 2022
Nature of transaction: Participation in Employee Share Purchase Scheme
Name of any other party or parties to the transaction (if known):
Fisher & Paykel Healthcare Employee Share
Purchase Trustee Limited
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily converted into a
cash value, describe the consideration:
$1,495.92
Number of financial products to which the transaction related:
71

If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details:
Whether relevant interests were acquired or disposed of during a closed period:Not Applicable
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal
Class of quoted financial products:
(a) Options to acquire Ordinary Shares
(b) Peformance Share Rights
Nature of relevant interest:
(a) Beneficial
(b) Beneficial
For that relevant interest:
Number held in class:
(a) 282,391
(b) 91,787
Current registered holder(s):Lewis George Gradon
For a derivative relevant interest:
Type of derivative:Not Applicable
Details of derivative:
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative relevant interest:
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Certification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:7 March 2022
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
7 March 2022
Date of last disclosure:
3 September 2021
Director or senior manager giving disclosure
Full name(s):
Lyndal Jane York
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Financial Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary shares
Nature of the affected relevant interest(s):
Beneficial interest in shares issued to a trustee under an
Employee Share Scheme
For that relevant interest
Number held in class before acquisition or disposal:
1,000
Number held in class after acquisition or disposal:
1,044
Current registered holder(s):
Alexander Eric York, Fisher & Paykel Healthcare Employee
Share Purchase Trustee Limited
Registered holder(s) once transfers are registered:
Alexander Eric York, Lyndal Jane York (on completion of
three year holding period)
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
One
Details of transactions requiring disclosure-
Date of transaction:
28 January 2020

Nature of transaction: Participation in Employee Share Purchase Scheme
Name of any other party or parties to the transaction (if known):
Fisher & Paykel Healthcare Employee Share Purchase
Trustee Limited
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:$497.70
Number of financial products to which the transaction related:
44
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were aquired or disposed of during a closed period:
Not Applicable
Whether prior written clearance was provided to allow the aquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
(a) Options to acquire Ordinary Shares
(b) Peformance Share Rights
Nature of relevant interest:
(a) Beneficial
(b) Beneficial
For that relevant interest,-
Number held in class:
(a) 29,781
(b) 9,406
Current registered holder(s):
Lyndal Jane York
For a derivative relevant interest,-
Type of derivative:
Not Applicable
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Cerification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:7 March 2022
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
7 March 2022
Date of last disclosure:
7 March 2022
Director or senior manager giving disclosure
Full name(s):
Lyndal Jane York
Name of listed issuer:
Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:
Chief Financial Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial interest in shares issued to a trustee under an
Employee Share Scheme
For that relevant interest
Number held in class before acquisition or disposal:
1,044
Number held in class after acquisition or disposal:
1,115
Current registered holder(s):
Alexander Eric York, Fisher & Paykel Healthcare Employee
Share Purchase Trustee Limited
Registered holder(s) once transfers are registered:
Alexander Eric York, Lyndal Jane York (on completion of
three year holding period)
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
One
Details of transactions requiring disclosure-
Date of transaction:
28 February 2022

Nature of transaction: Participation in Employee Share Purchase Scheme
Name of any other party or parties to the transaction (if known):
Fisher & Paykel Healthcare Employee Share Purchase
Trustee Limited
The consideration, expressed in New Zealand dollars, paid or received for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$1,495.92
Number of financial products to which the transaction related:
71
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were aquired or disposed of during a closed period:
Not applicable
Whether prior written clearance was provided to allow the aquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
(a) Options to acquire Ordinary Shares
(b) Peformance Share Rights
Nature of relevant interest:
(a) Beneficial
(b) Beneficial
For that relevant interest,-
Number held in class:
(a) 69,624
(b) 22,741
Current registered holder(s):
Lyndal Jane York
For a derivative relevant interest,-
Type of derivative:
Not Applicable
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Cerification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:7 March 2022
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
7 March 2022
Date of last disclosure:
20 September 2021
Director or senior manager giving disclosure
Full name(s):Paul Nigel Shearer
Name of listed issuer:Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:Senior Vice President - Sales & Marketing
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial interest in shares issued to a trustee under an
Employee Share Scheme
For that relevant interest-
Number held in class before acquisition or disposal:
405,398
Number held in class after acquisition or disposal:
405,486
Current registered holder(s):
Paul Nigel Shearer; Shearer Family Trust; Fisher & Paykel
Healthcare Employee Share Purchase Trustee Limited
Registered holder(s) once transfers are registered:Paul Nigel Shearer; Shearer Family Trust
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
One
Details of transactions requiring disclosure-
Date of transaction:
28-Jan-20
Nature of transaction: Participation in Employee Share Purchase Scheme
Name of any other party or parties to the transaction (if known):
Fisher & Paykel Healthcare Employee Share Purchase
Trustee Limited
The consideration, expressed in New Zealand dollars, paid or recieved for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$1,490.81
Number of financial products to which the transaction related:
88
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were aquired or disposed of during a closed period:
Not applicable
Whether prior written clearance was provided to allow the aquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
(a) Options to acquire Ordinary Shares
(b) Peformance Share Rights
Nature of relevant interest:
(a) Beneficial
(b) Beneficial
For that relevant interest,-
Number held in class:
(a) 238,031
(b) 78,983
Current registered holder(s):
Paul Nigel Shearer
For a derivative relevant interest,-
Type of derivative:
Not Applicable
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Cerification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:7 March 2022
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer: Fisher & Paykel Healthcare Corporation Limited
Date this disclosure made:
7 March 2022
Date of last disclosure:
7 March 2022
Director or senior manager giving disclosure
Full name(s):Paul Nigel Shearer
Name of listed issuer:Fisher & Paykel Healthcare Corporation Limited
Name of related body corporate (if applicable):
Position held in listed issuer:Senior Vice President - Sales & Marketing
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial interest in shares issued to a trustee under an
Employee Share Scheme
For that relevant interest-
Number held in class before acquisition or disposal:
384,897
Number held in class after acquisition or disposal:
384,968
Current registered holder(s):
Paul Nigel Shearer; Shearer Family Trust; Fisher & Paykel
Healthcare Employee Share Purchase Trustee Limited
Registered holder(s) once transfers are registered:Paul Nigel Shearer; Shearer Family Trust
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
Not Applicable
Class of underlying financial products:
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
One
Details of transactions requiring disclosure-
Date of transaction:
28-Feb-22
Nature of transaction: Participation in Employee Share Purchase Scheme
Name of any other party or parties to the transaction (if known):
Fisher & Paykel Healthcare Employee Share Purchase
Trustee Limited
The consideration, expressed in New Zealand dollars, paid or recieved for the acquisition
or disposal. If the consideration was not in cash and cannot be readily by converted into a
cash value, describe the consideration:
$1,495.92
Number of financial products to which the transaction related:
71
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were aquired or disposed of during a closed period:
Not applicable
Whether prior written clearance was provided to allow the aquisition or disposal to
proceed during the closed period:
Date of the prior written clearance (if any):
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
(a) Options to acquire Ordinary Shares
(b) Peformance Share Rights
Nature of relevant interest:
(a) Beneficial
(b) Beneficial
For that relevant interest,-
Number held in class:
(a) 136,384
(b) 44,352
Current registered holder(s):
Paul Nigel Shearer
For a derivative relevant interest,-
Type of derivative:
Not Applicable
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative:
Cerification
I certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all persons
for whom it is made.
Signature of director or officer:
Date of signature:7 March 2022
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person: